Table 2 Contribution of bone marrow aspiration to diagnosis and treatment

1

b

Hemophagocytic syndrome

No

2 (a)

b

Maturation arrest of granulocyte precursors

No

3 (a)

c

Acute transformation of CMML

DFLST

4

d

Maturation arrest of granulocyte precursors

No

5 (a)

c

Maturation arrest of granulocyte precursors

No

6

c

No (normal marrow)

Addition of erythropoietin

7

c

Marginal zone lymphoma

No

8 (a)

c

No (normal marrow)

Addition of dasatinib

9 (a)

e

Maturation arrest of granulocyte precursors

Discontinuation of TMP/SMX

10

e

Hemophagocytic syndrome

No

11

c

Lymphocytic lymphoma

No

12

e

No (presence of phagocytic histiocytes)

Addition of etoposide

13

e

Myelodysplastic syndrome

No

14

b

Hemophagocytic syndrome

No

15

c

Diffuse large B cell lymphoma

Addition of COP (g)

16

c

Marginal zone lymphoma

No

17

d

Maturation arrest of granulocyte precursors

No

18 (a)

c

Acute monocytic leukemia

DFLST

19

c

Acute myeloid leukemia

DFLST

20

e

Hemophagocytic syndrome

No

21

e

Hemophagocytic syndrome

No

22

c

Myelodysplastic syndrome

No

23 (a)

c

Relapsed multiple myeloma

No

24

e

Hemophagocytic syndrome

No

25

d

Maturation arrest of granulocyte precursors

Discontinuation of tacrolimus

26

e

Hemophagocytic syndrome

No

27 (a)

c

Hemophagocytic syndrome

No

28

c

Multiple myeloma

No

29

e

Myelodysplastic syndrome

No

30

e

Myelodysplastic syndrome

No

31

b

Hemophagocytic syndrome

No

32

f

Diffuse large B cell lymphoma

Addition of COP (g)

33 (a)

c

Myelodysplastic syndrome

No

34

e

Hemophagocytic syndrome

Addition of etoposide

35 (a)

c

Hemophagocytic syndrome

No

36

e

Hemophagocytic syndrome

No

37

d

Maturation arrest of granulocyte precursors

Addition of lenogastrim

38

d

Maturation arrest of granulocyte precursors

Discontinuation of amoxicillin

39

d

Maturation arrest of granulocyte precursors

Addition of lenogastrim

40 (a)

c

Maturation arrest of granulocyte precursors

No